155 related articles for article (PubMed ID: 38483404)
1. Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity.
Atallah A; Grossman A; Nauman RW; Paré JF; Khan A; Siemens DR; Cotechini T; Graham CH
Int J Cancer; 2024 Jul; 155(2):352-364. PubMed ID: 38483404
[TBL] [Abstract][Full Text] [Related]
2. BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer.
Lombardo KA; Obradovic A; Singh AK; Liu JL; Joice G; Kates M; Bishai W; McConkey D; Chaux A; Eich ML; Rezaei MK; Netto GJ; Drake CG; Tran P; Matoso A; Bivalacqua TJ
J Pathol; 2022 Feb; 256(2):223-234. PubMed ID: 34731491
[TBL] [Abstract][Full Text] [Related]
3. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
4. Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.
Nunez-Nateras R; Castle EP; Protheroe CA; Stanton ML; Ocal TI; Ferrigni EN; Ochkur SI; Jacobsen EA; Hou YX; Andrews PE; Colby TV; Lee NA; Lee JJ
Urol Oncol; 2014 Jan; 32(1):45.e23-30. PubMed ID: 24055426
[TBL] [Abstract][Full Text] [Related]
5. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.
Biot C; Rentsch CA; Gsponer JR; Birkhäuser FD; Jusforgues-Saklani H; Lemaître F; Auriau C; Bachmann A; Bousso P; Demangel C; Peduto L; Thalmann GN; Albert ML
Sci Transl Med; 2012 Jun; 4(137):137ra72. PubMed ID: 22674550
[TBL] [Abstract][Full Text] [Related]
6. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.
Larsen ES; Joensen UN; Poulsen AM; Goletti D; Johansen IS
APMIS; 2020 Feb; 128(2):92-103. PubMed ID: 31755155
[TBL] [Abstract][Full Text] [Related]
7. Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
Ke ZB; Chen H; Chen JY; Cai H; Lin YZ; Sun XL; Huang JB; Zheng QS; Wei Y; Xue XY; Xu N
Clin Nutr; 2021 Dec; 40(12):5792-5801. PubMed ID: 34775222
[TBL] [Abstract][Full Text] [Related]
8. Preoperative sarcopenia and systemic immune-inflammation index can predict response to intravesical Bacillus Calmette-Guerin instillation in patients with non-muscle invasive bladder cancer.
Liu P; Chen S; Gao X; Liang H; Sun D; Shi B; Zhang Q; Guo H
Front Immunol; 2022; 13():1032907. PubMed ID: 36225922
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T Cells and Tumor-Associated Macrophages in the Tumor Microenvironment in Non-Muscle Invasive Bladder Cancer Treated with Intravesical Bacille Calmette-Guérin: A Long-Term Follow-Up Study of a Japanese Cohort.
Miyake M; Tatsumi Y; Gotoh D; Ohnishi S; Owari T; Iida K; Ohnishi K; Hori S; Morizawa Y; Itami Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Shimada K; Konishi N; Tanaka N; Fujimoto K
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29048388
[TBL] [Abstract][Full Text] [Related]
10. Intravesical Pseudomonas aeruginosa mannose-sensitive Hemagglutinin vaccine triggers a tumor-preventing immune environment in an orthotopic mouse bladder cancer model.
Wang B; He Z; Yu H; Ou Z; Chen J; Yang M; Fan X; Lin T; Huang J
Cancer Immunol Immunother; 2022 Jun; 71(6):1507-1517. PubMed ID: 34718847
[TBL] [Abstract][Full Text] [Related]
11. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
12. Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
Hori S; Miyake M; Tatsumi Y; Morizawa Y; Nakai Y; Onishi S; Onishi K; Iida K; Gotoh D; Itami Y; Tanaka N; Fujimoto K
Oncol Rep; 2019 Mar; 41(3):1863-1874. PubMed ID: 30628699
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
[TBL] [Abstract][Full Text] [Related]
14. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway.
Mao MH; Huang HB; Zhang XL; Li K; Liu YL; Wang P
Biomed Pharmacother; 2018 Nov; 107():1093-1103. PubMed ID: 30257321
[TBL] [Abstract][Full Text] [Related]
15. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
[TBL] [Abstract][Full Text] [Related]
16. Intravesical oncolytic virotherapy and immunotherapy for non-muscle-invasive bladder cancer mouse model.
Smelser WW; Wang J; Ogden KM; Chang SS; Kirschner AN
BJU Int; 2023 Sep; 132(3):298-306. PubMed ID: 36961272
[TBL] [Abstract][Full Text] [Related]
17. Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cell-Mediated Tumor Regression in the MB49 Bladder Cancer Model.
Domingos-Pereira S; Sathiyanadan K; La Rosa S; Polák L; Chevalier MF; Martel P; Hojeij R; Derré L; Haefliger JA; Jichlinski P; Nardelli-Haefliger D
Cancer Immunol Res; 2019 Apr; 7(4):621-629. PubMed ID: 30696629
[TBL] [Abstract][Full Text] [Related]
18. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
[TBL] [Abstract][Full Text] [Related]
19. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
[TBL] [Abstract][Full Text] [Related]
20. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]